Welcome
2020 Pharmacogenomics Access and Reimbursement Symposium
Uniting Internationally to Advance Precision Medicine
October 7-8, 2020, Washington DC, USA
The Golden Helix Foundation and the Pharmacogenomics Access & Reimbursement Coalition (PARC) are proud to announce our inaugural hosting of the Pharmacogenomics Access & Reimbursement Symposium (PARS) on October 8, 2020, at the National Academy of Sciences in Washington D.C.
The theme of the symposium is “Uniting Internationally to Advance Precision Medicine”.
A primary goal of PARC continues to be the exchange of ideas and experiences among stakeholders that share similar opportunities and challenges in pharmacogenomics. The symposium will provide presentations by industry and thought leaders during key sessions including Health Technology Assessment, Health Economics and Value-based Payment Strategies for Pharmacogenomics.
Decision-makers from industry, government agencies, payer organizations, health systems and health policy organizations will convene to define opportunities to improve patient access to precision medicine through best practices, successful reimbursement models, high quality economic evaluations and strategic alignment.
We anticipate international representation from the Golden Helix Foundation’s Genomic Medicine Alliance of 1,400 members from over 70 countries around the world. Live symposium webcasting will allow virtual attendance to expand reach and will increase exposure of your support.
We look forward to your partnership in our efforts to improve patient access to safer and more effective treatments using precision medicine.
Sincerely,
The PARS 2020 Organizing Committee
Organized by:
Endorsed by:
About PARC
Pharmacogenomics Access and Reimbursement Coalition (PARC) represents a group of individuals from a variety of healthcare backgrounds coming together to address issues related to access, affordability and reimbursement of pharmacogenomic (PGx) testing for patients.
The coalition is comprised of individuals from institutions around the world. Together, we aim to overcome barriers that are affecting patients worldwide. PARC seeks to leverage tools and technologies that can increase patient access and affordability to testing that can improve their clinical outcome.
PGx testing has a tremendous potential to impact patient care. PARC aims to collaborate with individuals and institutions to streamline resources that can support payer coverage for PGx testing.
With payer support, the research that goes into developing and utilizing PGx testing can continue to grow.
Venue
Venue
The venue of PARS 2020 is the landmark building of the U.S. National Academy of Sciences. The conference will be held in the Fred Kavli auditorium. The National Academy of Sciences is a private non-profit society of distinguished scholars, established by an Act of Congress, signed by President Abraham Lincoln in 1862. The National Academy of Sciences is charged with providing independent advice on matters related to science and technology.
The newly built Fred Kavli 670-seat auditorium is used extensively for scientific symposia and meetings. Its interior is designed to eliminate acoustic focal points and to ensure an optimal distribution of sound.
Speakers
Organizing Committee
Benjamin Brown; Dynamic Life Sciences, USA
Christine Formea, Pharm.D., Intermountain Healthcare, USA
Jyothsna Giri, M.D.; Mayo Clinic, USA
Nina Gonzaludo, Ph.D.; Illumina, USA
Shawn Jones, Ph.D.; Texas Tech University Health Sciences Center, USA
Lina Li, MBA, RPRD Diagnostics, USA
Christina Mitropoulou, MBA; The Golden Helix Foundation, UK
George P. Patrinos, Ph.D.; University of Patras, Greece
Sara Rogers, Pharm.D.; American Society of Pharmacovigilance, USA
Scientific Program
Scientific Program
Topics to be discussed:
· Comparative Effectiveness Research for pharmacogenomics
· State-of-the-art value assessment frameworks for pharmacogenetics testing
· Pulling back the curtain on real world evidence and pharmacogenomics
· Gene-drug formulary: new frontiers in cost containment
· New methods and measures for improved economic evaluation and efficiency measures in pharmacogenomics to gain advances in increasing value and promote health seeking behavior
· Economic evaluations: ensuring quality trials and addressing challenges
· Identifying the most promising payer engagement strategies
· Strategies for producers and payers to collaborate throughout the product life cycle
Draft Scientific Program
October 7, 2020
Informal get together (venue to be confirmed)
October 8, 2020
Breakfast
Opening Keynote Presentation
Session 1: Health Technology Assessment / Health policy
Break
Session 2: Health Economics
Lunch
Session 3: Value-based payment models for pharmacogenomics
Networking break
Session 4: Round table, Closing keynote presentation
Dinner recention (Smithsonian American Art Museum)
Registration
Registration
